Literature DB >> 19384931

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.

Chitra Hosing1, Rima M Saliba, Sheena Ahlawat, Martin Körbling, Partow Kebriaei, Amin Alousi, Marcos De Lima, Julia-Grace Okoroji, John McMannis, Muzaffar Qazilbash, Paolo Anderlini, Sergio Giralt, Richard E Champlin, Issa Khouri, Uday Popat.   

Abstract

The purpose of this retrospective study was to determine the incidence and predictive factors if any, of mobilization failure in lymphoma patients referred for autologous stem cell transplantation. A total of 588 lymphoma patients were referred for transplant consultation from January 2003 to December 2004. Predictors of mobilization failure were evaluated using logistic regression analysis including diagnosis, mobilization regimen, age, sex, type and number of prior chemotherapies, bone marrow cellularity, platelet count, white count, prior bone marrow involvement with malignancy, and prior radiation therapy. Two hundred and six patients were eligible for transplantation and underwent stem cell mobilization. Twenty-nine (14%) patients failed to mobilize adequate stem cells after the first attempt. For the entire group age (>or=60 versus <60 years), diagnosis (Hodgkin's versus non-Hodgkin's lymphoma), use of cytokines alone, platelet count <150 x 10(9)/L, and bone marrow cellularity <30% were significant predictors for mobilization failure on univariate analysis. In view of small number of patients multivariate analysis was not possible. However, a low platelet count (150 x 10(9)/L) was the only significant predictor when the analysis was restricted to non-Hodgkin's lymphoma patients who were mobilized with chemotherapy. Mobilization failure rates are higher in patients with non-Hodgkin's lymphoma compared with those with Hodgkin's lymphoma. In the subset of patients who undergo chemomobilization for non-Hodgkin's lymphoma platelet count at the time of mobilization is a predictor of mobilization failure.

Entities:  

Mesh:

Year:  2009        PMID: 19384931      PMCID: PMC4112361          DOI: 10.1002/ajh.21400

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  25 in total

1.  High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

Authors:  C Tarella; M Di Nicola; D Caracciolo; F Zallio; A Cuttica; P Omedè; P Bondesan; M Magni; P Matteucci; A Gallamini; A Pileri; A M Gianni
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

2.  Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

Authors:  M L Donato; R E Champlin; K W Van Besien; M Korbling; F Cabanillas; P Anderlini; J G Gajewski; J Lauppe; A Durett; B Andersson; S Giralt; I Khouri; F Hagemeister; J E Romaguera; A Sarris; P McLaughlin; A Younes; C Ippoliti; D A Blamble; J Hester; A Gee; M A Rodriguez
Journal:  Leuk Lymphoma       Date:  1999-10

3.  Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients.

Authors:  Saad Akhtar; Amr El Weshi; Mohemmed Rahal; Yasser Khafaga; Abdelghani Tbakhi; Hind Humaidan; Irfan Maghfoor
Journal:  Leuk Lymphoma       Date:  2008-04

4.  Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

Authors:  Issa F Khouri; Rima M Saliba; Chitra Hosing; Grace-Julia Okoroji; Sandra Acholonu; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Michele L Donato; Luis Fayad; Segio Giralt; Roy Jones; Martin Korbling; Farzaneh Maadani; John T Manning; Barbara Pro; Elizabeth Shpall; Anas Younes; Peter McLaughlin; Richard E Champlin
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.

Authors:  T Kewalramani; A D Zelenetz; E E Hedrick; G B Donnelly; S Hunte; A C Priovolos; J Qin; N C Lyons; J Yahalom; S D Nimer; C H Moskowitz
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

6.  Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation.

Authors:  V Pavone; F Gaudio; G Console; U Vitolo; P Iacopino; A Guarini; V Liso; T Perrone; A Liso
Journal:  Bone Marrow Transplant       Date:  2006-04       Impact factor: 5.483

7.  Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies.

Authors:  Reem M Ameen; Salem H Alshemmari; Dana Alqallaf
Journal:  Clin Lymphoma Myeloma       Date:  2008-04

8.  Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Authors:  Iskra Pusic; Shi Yuan Jiang; Scott Landua; Geoffrey L Uy; Michael P Rettig; Amanda F Cashen; Peter Westervelt; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Diane S Sempek; Angela L Smith; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

Review 9.  Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status.

Authors:  P Anderlini
Journal:  Cytotherapy       Date:  2002       Impact factor: 5.414

10.  Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation.

Authors:  L N Gordan; M W Sugrue; J W Lynch; K D Williams; S A Khan; J R Wingard; J S Moreb
Journal:  Leuk Lymphoma       Date:  2003-05
View more
  23 in total

1.  Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.

Authors:  Santosh Saraf; Hiroto Araki; Benjamin Petro; Youngmin Park; Simona Taioli; Kazumi G Yoshinaga; Emre Koca; Damiano Rondelli; Nadim Mahmud
Journal:  Transfusion       Date:  2014-11-02       Impact factor: 3.157

Review 2.  Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization.

Authors:  Jonathan Hoggatt; Jennifer M Speth; Louis M Pelus
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

3.  Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Authors:  Andreas Humpe; Ute Buwitt-Beckmann; Natalie Schub; Martin Gramatzki; Andreas Günther
Journal:  Transfus Med Hemother       Date:  2013-07-25       Impact factor: 3.747

4.  Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.

Authors:  Ivana N Micallef; Patrick J Stiff; Edward A Stadtmauer; Brian J Bolwell; Auayporn P Nademanee; Richard T Maziarz; Angela M Partisano; Sachin Marulkar; John F DiPersio
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

5.  Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Authors:  Peter Martin; Zhengming Chen; Bruce D Cheson; Katherine S Robinson; Michael Williams; Saurabh A Rajguru; Jonathan W Friedberg; Richard H van der Jagt; Ann S LaCasce; Robin Joyce; Kristen N Ganjoo; Nancy L Bartlett; Bernard Lemieux; Ari VanderWalde; Jordan Herst; Jeffrey Szer; Michael H Bar; Fernando Cabanillas; Anthony J Dodds; Paul G Montgomery; Bryn Pressnail; Tricia Ellis; Mitchell R Smith; John P Leonard
Journal:  Br J Haematol       Date:  2017-04-17       Impact factor: 6.998

6.  Diabetes impairs hematopoietic stem cell mobilization by altering niche function.

Authors:  Francesca Ferraro; Stefania Lymperi; Simón Méndez-Ferrer; Borja Saez; Joel A Spencer; Beow Y Yeap; Elena Masselli; Gallia Graiani; Lucia Prezioso; Elisa Lodi Rizzini; Marcellina Mangoni; Vittorio Rizzoli; Stephen M Sykes; Charles P Lin; Paul S Frenette; Federico Quaini; David T Scadden
Journal:  Sci Transl Med       Date:  2011-10-12       Impact factor: 17.956

7.  Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF.

Authors:  A A Maschan; D N Balashov; E E Kurnikova; P E Trakhtman; E V Boyakova; E V Skorobogatova; G A Novichkova; M A Maschan
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

8.  Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.

Authors:  Rajiv Kumar; Rajan Kapoor; Bhushan Asthana; Jasjit Singh; Tarun Verma; Rajesh Chilaka; N K Singh; Ajay Sharma; S Das; Velu Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-03       Impact factor: 0.900

Review 9.  Advances in stem cell mobilization.

Authors:  Rusudan K Hopman; John F DiPersio
Journal:  Blood Rev       Date:  2014-01-14       Impact factor: 8.250

10.  Stem cell mobilization in HIV seropositive patients with lymphoma.

Authors:  Alessandro Re; Chiara Cattaneo; Cristina Skert; Pascual Balsalobre; Mariagrazia Michieli; Mark Bower; Andrés J M Ferreri; Marcus Hentrich; José M Ribera; Bernardino Allione; Philipp Schommers; Silvia Montoto; Camillo Almici; Pierino Ferremi; Mario Mazzucato; Salvatore Gattillo; Salvatore Casari; Michele Spina; José L Diez-Martin; Umberto Tirelli; Giuseppe Rossi
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.